Evidence map›Paper›PMID 40519164›Full record

ArticleThe Journal of clinical investigation2025

Hemodynamic forces prevent myxomatous valve disease in mice through KLF2/4 signaling.

Jesse A Pace, Lauren M Goddard, Courtney C Hong, Liqing Wang, Jisheng Yang, Mei Chen, Yitian Xu, Martin H Dominguez, Siqi Gao, Xiaowen Chen and 8 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Lymphatic therapies open the valve in Marfan syndrome.The Journal of clinical investigation · 2026
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jesse A PaceCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lauren M GoddardCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Courtney C HongCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Liqing WangDivision of Transplant Immunology, Department of Pathology and Laboratory Medicine, and Biesecker Center for Pediatric Liver Disease, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jisheng YangCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mei ChenCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yitian XuCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Martin H DominguezCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Siqi GaoCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Xiaowen ChenCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Patricia Mericko-IshizukaCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Can TanDepartment of Medicine, Feinberg Cardiovascular and Renal Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Tsutomu KumeDepartment of Medicine, Feinberg Cardiovascular and Renal Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Wenbao YuDivision of Oncology and Center for Childhood Cancer Research, Center for Single Cell Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kai TanDivision of Oncology and Center for Childhood Cancer Research, Center for Single Cell Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Wayne W HancockDivision of Transplant Immunology, Department of Pathology and Laboratory Medicine, and Biesecker Center for Pediatric Liver Disease, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Giovanni FerrariDepartment of Surgery, Department of Biomedical Engineering, Columbia University, New York, New York, USA.
Mark L KahnCardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Supplement to Serotonin Signaling in Mitral Valve Homeostasis, Maintenance and RestorationR01HL131872 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Giovanni Ferrari, Robert J Levy · 2016 to 2026
$7.7M
Flow and endothelial signaling in acquired myxomatous valve diseaseR01HL153224 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2020 to 2023
$2.9M
Hemodynamics and KLF2/4 regulate myxomatous valve pathogenesisF30HL173955 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jesse Pace · 2024 to 2026
$147k
NHLBI NIH HHS F30 HL173955NHLBI NIH HHS R01 HL131872NHLBI NIH HHS R01 HL153224
6 · The paper itself

Abstract

Myxomatous valve disease (MVD) is the most common form of cardiac valve disease in the developed world. A small fraction of MVD is syndromic and arises in association with matrix protein defects such as those in Marfan syndrome, but most MVD is acquired later in life through an undefined pathogenesis. The KLF2/4 transcription factors mediate endothelial fluid shear responses, including those required to create cardiac valves during embryonic development. Here we test the role of hemodynamic shear forces and downstream endothelial KLF2/4 in mature cardiac valves. We find that loss of hemodynamic forces in heterotopically transplanted hearts or genetic deletion of KLF2/4 in cardiac valve endothelium confers valve cell proliferation and matrix deposition associated with valve thickening, findings also observed in mice expressing the mutant fibrillin-1 protein known to cause human MVD. Transcriptomic and histologic analysis reveals increased monocyte recruitment and TGF-β signaling in both fibrillin-1-mutant valves and valves lacking hemodynamic forces or endothelial KLF2/4 function, but only loss of TGF-β/SMAD signaling rescued myxomatous changes. We observed reduced KLF2/4 expression and augmented SMAD signaling in human MVD. These studies identify hemodynamic activation of endothelial KLF2/4 as an environmental homeostatic regulator of cardiac valves and suggest that non-syndromic MVD may arise in association with disturbed blood flow across the aging valve.

Indexed as

Heart Valve DiseasesHemodynamicsKruppel-Like Transcription FactorsSignal TransductionAdipokinesAnimalsFibrillin-1HumansKruppel-Like Factor 4MiceMice, KnockoutTransforming Growth Factor betaAdipokinesFbn1 protein, mouseFibrillin-1KLF2 protein, humanKlf2 protein, mouseKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Kruppel-Like Transcription FactorsTransforming Growth Factor betaCardiologyCardiovascular diseaseEndothelial cellsVascular biology

Identifiers

PMID40519164
PMCPMC12165810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.